Roth Capital Starts NovaBay Pharmaceuticals (NBY) at Buy
Tweet
Share
E-mailGet Alerts NBY Hot Sheet
Price: $1.95 --0%
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Roth Capital initiates coverage on NovaBay Pharmaceuticals (NYSE: NBY) with a Buy rating and a price target of $5.50.
For an analyst ratings summary and ratings history on NovaBay Pharmaceuticals click here. For more ratings news on NovaBay Pharmaceuticals click here.
Shares of NovaBay Pharmaceuticals closed at $2.35 Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Starts Faeth Therapeutics (FTH) at Buy
- BMO Capital Starts Broadcom Limited (AVGO) at Outperform
- BofA Securities Starts Mobility Global (MBGL) at Neutral
Create E-mail Alert Related Categories
New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
